Morse Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.72M | Buy |
10,565
+142
| +1% | +$66.2K | 0.98% | 30 |
|
|
2025
Q4 | $4.73M | Buy |
10,423
+118
| +1% | +$50.9K | 0.94% | 29 |
|
|
2025
Q3 | $4.04M | Buy |
10,305
+18
| +0.2% | +$7.52K | 0.81% | 37 |
|
|
2025
Q2 | $4.58M | Sell |
10,287
-174
| -2% | -$80.2K | 1% | 31 |
|
|
2025
Q1 | $5.07M | Sell |
10,461
-94
| -0.9% | -$43.8K | 1.28% | 26 |
|
|
2024
Q4 | $4.25M | Buy |
10,555
+578
| +6% | +$268K | 0.97% | 27 |
|
|
2024
Q3 | $4.64M | Sell |
9,977
-138
| -1% | -$66.3K | 1% | 26 |
|
|
2024
Q2 | $4.74M | Sell |
10,115
-80
| -0.8% | -$34.7K | 1.15% | 28 |
|
|
2024
Q1 | $4.26M | Buy |
10,195
+706
| +7% | +$298K | 1.09% | 33 |
|
|
2023
Q4 | $3.86M | Buy |
9,489
+1,547
| +19% | +$571K | 1.14% | 32 |
|
|
2023
Q3 | $2.76M | Buy |
7,942
+621
| +8% | +$217K | 0.87% | 39 |
|
|
2023
Q2 | $2.58M | Buy |
7,321
+1,425
| +24% | +$480K | 0.78% | 42 |
|
|
2023
Q1 | $1.86M | Buy |
5,896
+681
| +13% | +$204K | 0.63% | 52 |
|
|
2022
Q4 | $1.51M | Buy |
5,215
+1,278
| +32% | +$389K | 0.55% | 57 |
|
|
2022
Q3 | $1.14M | Buy |
3,937
+2,105
| +115% | +$606K | 0.43% | 67 |
|
|
2022
Q2 | $516K | Buy |
1,832
+375
| +26% | +$100K | 0.17% | 109 |
|
|
2022
Q1 | $380K | Buy |
+1,457
| New | +$346K | 0.09% | 139 |
|
|
2021
Q1 | – | Sell |
-1,268
| Closed | -$300K | – | 163 |
|
|
2020
Q4 | $300K | Sell |
1,268
-9,710
| -88% | -$2.23M | 0.08% | 118 |
|
|
2020
Q3 | $2.99M | Buy |
10,978
+2,411
| +28% | +$665K | 0.96% | 28 |
|
|
2020
Q2 | $2.49M | Buy |
8,567
+4,837
| +130% | +$1.31M | 0.89% | 33 |
|
|
2020
Q1 | $888K | Buy |
3,730
+2,419
| +185% | +$555K | 0.42% | 56 |
|
|
2019
Q4 | $287K | Buy |
+1,311
| New | +$265K | 0.1% | 113 |
|
|
2019
Q3 | – | Sell |
-9,628
| Closed | -$1.77M | – | 142 |
|
|
2019
Q2 | $1.77M | Sell |
9,628
-2,880
| -23% | -$503K | 0.52% | 56 |
|
|
2019
Q1 | $2.3M | Buy |
12,508
+6,795
| +119% | +$1.26M | 0.69% | 45 |
|
|
2018
Q4 | $947K | Sell |
5,713
-10,102
| -64% | -$1.75M | 0.34% | 70 |
|
|
2018
Q3 | $3.05M | Buy |
15,815
+9,764
| +161% | +$1.74M | 0.8% | 40 |
|
|
2018
Q2 | $1.03M | Buy |
6,051
+675
| +13% | +$105K | 0.28% | 83 |
|
|
2018
Q1 | $876K | Buy |
5,376
+46
| +0.9% | +$7.51K | 0.24% | 86 |
|
|
2017
Q4 | $799K | Buy |
5,330
+180
| +3% | +$26.7K | 0.22% | 87 |
|
|
2017
Q3 | $783K | Buy |
+5,150
| New | +$775K | 0.23% | 86 |
|
Other funds holding VRTX
VCM
VPM
Morse Asset Management's VRTX Position: Q1 2026 in Review
Morse Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 1.4% in Q1 2026, buying an estimated $66.2K and bringing the position to 10,565 shares worth $4.72M. The position accounts for 0.98% of the portfolio, ranked #30.
Morse Asset Management first reported a position in VRTX in Q3 2017 and has held it in 30 quarters since. The position peaked at $5.07M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Morse Asset Management held 10,565 shares of Vertex Pharmaceuticals worth $4.72M as of Q1 2026.
- Morse Asset Management bought 142 Vertex Pharmaceuticals shares in Q1 2026, an estimated $66.2K.
- Vertex Pharmaceuticals made up 0.98% of Morse Asset Management's portfolio in Q1 2026, its #30 holding.
- Morse Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 30 quarters since.
- Morse Asset Management's Vertex Pharmaceuticals position peaked at $5.07M in Q1 2025.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Morse Asset Management's 13F filing for Q1 2026, filed 14 May 2026.